​​​​​​​Supervisory Board of Epigenomics AG appoints Jens Ravens as Chief Financial Officer

Supervisory Board of Epigenomics AG appoints Jens Ravens as Chief Financial Officer

• Jens Ravens is an internationally experienced leader with in-depth experience in Controlling, Finance, M&A, IT, Legal, and Human Resources
• New Chief Financial Officer to join Epigenomics on February 1, 2022

Berlin (Germany) and San Diego, CA (U.S.A.), December 14, 2021 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the “Company”), an oncology focused molecular diagnostics company, announced today that the Supervisory Board appointed Jens Ravens as Chief Financial Officer with effect from February 1, 2022. Jens Ravens, who has extensive financial executive experience will become a member of the Executive Board of Epigenomics and oversee the company’s financial and administrative functions.

Jens Ravens (52) has over 20 years of management experience in finance in various European companies. Prior to joining Epigenomics, Jens held several positions at the Hermes Group, Hamburg, part of the OTTO Group, predominantly as Vice President Controlling & Finance as well as Compliance & Risk Management Officer. There he had the financial responsibility for subsidiaries and national companies as well as cost responsibility and profit control responsibility. Previously, he was CFO and Managing Director at Pleon Germany in Düsseldorf and concurrently also served as CFO of Pleon Europe in London. Prior to that Jens worked as Finance Director and Member of the Executive Board at Interseroh CDI S.A. in Paris, France. He started his career at Deutsche Bank, where he worked in Equity Sales / Investment Banking. Jens Ravens holds a bilingual business degree (lic.rer.pol.) with distinction from University of Fribourg, Switzerland, and completed the advanced management programme at INSEAD, Fontainebleau, France.

Heino von Prondzynski, Chairman of the Supervisory Board: “We are very pleased to have Jens join Epigenomics AG as CFO with his in-depth management experience as well as his extensive expertise in finance. We are confident Jens will provide the financial leadership necessary to execute the company’s strategic vision.”

“I am looking forward to becoming part of the Epigenomics team,” said Jens Ravens. “Epigenomics has a tremendous opportunity ahead and I’m excited to play a leadership role in such an innovative organization.”

During the transition period, the current EVP Finance, Albert Weber, will continue to support the company as an advisor, as announced.
 

About Epigenomics
Epigenomics AG is a molecular diagnostics company focused on blood testing for the early detection of cancer. Based on its proprietary biomarker technology for the detection of methylated DNA, Epigenomics develops and markets blood tests for various cancer indications with high unmet medical need. Epigenomics’ lead product is the blood test Epi proColon(R) for the early detection of colorectal cancer. Epi proColon is approved by the U.S. Food and Drug Administration (FDA) and is marketed in the United States and Europe as well as other selected countries. HCCBloodTest, a blood test for the detection of liver cancer, have received the CE Mark for marketing in Europe.

For further information please visit www.epigenomics.com.

Contact:
Company
Epigenomics AG, Geneststrasse 5, 10829 Berlin,
Tel +49 (0) 30 24345 0, Fax +49 (0) 30 24345 555, E-Mail: contact@epigenomics.com

Investor Relations
IR.on AG, Frederic Hilke, Tel +49 221 9140 970, E-Mail: ir@epigenomics.com

Epigenomics legal disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any expected results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.